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Abstract 
Objectives: To investigate legacy effects at 14-years follow-up of all-cause and 
cardiovascular disease (CVD) mortality in ‘treatment naïve’(TN) or ‘previous 
treatment’ (PT) groups based on blood pressure (BP) lowering treatment status at 
baseline. 
Methods: A post-hoc observational study of the ALLHAT. We excluded participants 
with a previous history of CVD events. Cox proportional hazard model and 95% 
confidence interval (CI) were used to estimate the effects of TN on mortality 
outcomes. Also, a subgroup analysis by estimated 10-year Framingham risk score 
was performed.  
Results: In multivariable models adjusting for baseline and in-trial characteristics 
(BP values and number of BP medications as time-dependent variables), there was 
no statistically significant difference in 5-year and 14-year all-cause mortality with a 
hazard ratio (HR) of 0.93 (95% confidence interval 0.80-1.09) and HR 0.95 (0.88-
1.03) and in 5-year and 14-year CVD mortality HR 0.94 (0.72-1.23) and HR 0.93 
(0.80-1.08). In subgroup by absolute CVD risk, no heterogeneity of the association 
between TN and short- or long-term all-cause or CVD mortality were found. All 
comparisons are between the TN and PT groups. 
Conclusions: Physicians are concerned about ‘legacy effects’ of not treating 
individuals with a BP of 140 mmHg or over and low absolute risk. When treatment 
intensification was taken into consideration in the primary prevention population in 
this study, no adverse legacy effect as a result of baseline BP ‘treatment naivety’ 
was evident in 14 years of follow-up. The non-significant associations were 
consistent across the CVD risk subgroups. However, the results may be biased due 
to unobserved residual confounding and therefore should be interpreted with caution. 
Key Words: antihypertensive drug, cardiovascular disease, absolute cardiovascular 
risk, primary prevention, hypertension, all-cause mortality, CVD mortality. 
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Introduction 
Contemporary guidelines for the primary prevention of cardiovascular disease (CVD) 
are predominantly based on absolute CVD risk stratification for drug treatment 
decision making (e.g. blood pressure or cholesterol-lowering pharmacotherapies), 
not solely on blood pressure (BP) or blood cholesterol level1-5. As per the guidelines1-
3,5, individuals with a systolic BP above a traditional  threshold of 140/90 mmHg may 
not be treated. In current practice, some physicians remain concerned that delays in 
drug treatment may lead to irreversible target organ damage, so called adverse 
‘legacy effects’. Two systematic review and meta-analysis6, 7 have found beneficial 
‘legacy effects’ of BP lowering drug on reduced major CVD events that persisted 
after the trial termination even when all participants were back to usual care. 
However, both reviews incorporated primary and secondary population and  most of 
the included trials had no ‘actual’ placebo or untreated group when previous 
treatments were continued on top of the randomised group. The PREVEND-IT8, 9 
and Oslo10, 11 trials in which previous treatment was not permitted showed no 
significant adverse effects of placebo or no treatment on all-cause and CVD mortality 
in either 5-year or 10-year periods. Besides, a post-hoc observational study of the 
Second Australian National Blood Pressure study (ANBP2)12 in the elderly aged 65-
84 years observed a lower risk of all-cause and CVD mortality in ‘treatment naïve’ 
group (TN) who had no previous treatment at baseline, although the effects 
disappeared when the follow-up were extended to 10 years. Thus, adverse ‘legacy 
effect’ of delayed BP lowering drug treatment remains inconsistent. Due to the long 
established association between elevated BP and CVD risk, conducting a study 
having a placebo or untreated group seems to be ethically impossible. We 
conducted a similar study that investigated 14-year legacy effect of baseline BP 
‘treatment naivety’ in the Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT). A subgroup analysis by absolute CVD risk was 
performed to identify if a sub-group of the population may be harmed by delayed 
therapy. 
Methods 
Study design and population 
A post-hoc observational study of the Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT) was conducted13. ALLHAT was a 
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large multicentre, double-blinded, randomised active-controlled trial with 33,357 
participants from 623 North American centres (USA, Canada, Puerto Rico and the 
US Virgin Islands) aged 55 years or older, with systolic BP ranging from 140 to under 
180 and/or diastolic BP ranging from 90 to under 110 mmHg and at least one 
additional CVD risk factor.  
In this current analysis, 17,699 participants were excluded due to pre-existing 
major CVD events (myocardial infarction or stroke, coronary revascularization, major 
ST depression or T-wave inversion) and/or insufficient data for post-trial follow-up. 
This current study was designed as a post-hoc observational study. Participants 
were categorized by their BP lowering drug treatment status at baseline into a 
‘treatment naïve’ (TN) and ‘previous treated’ (PT) group. As presented in Figure 1, 
participants in the TN group had been untreated or treated for less than two months, 
whereas participants in the PT group had been treated for more than two months 
and their BP was controlled (<160/100 mmHg) with fewer than two BP-lowering 
medications. Before randomisation, all previous treatment was stopped or stepped 
down for 2-6 weeks. Participants were randomized to chlorthalidone 12.5 mg, 
amlodipine 2.5 mg or lisinopril 10 mg in a ratio of 1.7:1:1 respectively.  To obtain the 
BP treatment target of less than 140/90 mmHg, randomized drugs were titrated to 
maximum tolerated doses before adding open-label step 2 agents (atenolol, 
reserpine and clonidine) or step 3 agent (hydralazine). The in-trial period was 8 
years (1994-2002, median time of 4.9 years). After the study completion, participants 
returned to their usual care and were expected to continue their BP treatment, 
although there could be changes in treatment regimens. No information on 
medications, BP levels, outpatient morbidity, or laboratory values was collected in 
the post-trial phase. Information on mortality outcomes/participants survival were 
collected during 2006 and 2011 through the National Death Index or Social Security 
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Administration. More details on post-trial observation have been previously 
published14. The main outcomes during the in-trial and post-trial periods were all-
cause and CVD mortality (death due to CHD, stroke, HF, or other CVD).  
Subgroup by absolute CVD risk 
To investigate any difference of delayed treatment effects according to 
absolute CVD risk, we performed a subgroup analysis stratified by absolute CVD 
risk. The 10-year Framingham risk score (FRS)15 was used because it has been 
widely validated and calibrated in many different populations. Also, 10-year FRS by 
D’Agostino et al15 accounted for effects of BP lowering drug treatment on estimated 
CVD risk. Due to the variability of 10-year FRS thresholds used in different settings2, 
3, we considered <20%, 20 - 30% and >30% over 10 years as the conventional cut-
off points for low, moderate and high-risk group correspondingly in this analysis. 
Statistical analysis 
Differences in baseline characteristics between the TN and PT group were 
tested by ANOVA test for continuous variables and Chi-square test for categorical 
variables. Treatment effects were estimated by Cox proportional hazard model (HRs) 
and 95% confidence interval (CI) and were adjusted for age, race, gender, diabetes 
mellitus (DM), education, body mass index (BMI), current smoking, aspirin use, 
randomization group, systolic BP, diastolic BP, total cholesterol (TC), glucose, 
creatinine that were statistically different between PT and TN group (model A). The 
number of BP lowering drugs used in the in-trial phase and BP recorded from 
baseline to last visits were added in multivariate models as time-dependent variables 
(model B). In a sensitivity analysis, further adjusting for high-density lipoprotein 
cholesterol (HDL-c) or TC was performed. Also, we tested the effects of ‘treatment 
naïve’ when removing baseline BPs from multivariate models. 
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In the subgroup analysis by absolute CVD risk, interaction among CVD 
subgroup was tested by a baseline treatment status x absolute CVD risk stratification 
term in Cox models. As most of the missing data (BMI, TC), serum creatinine, DM, 
education status, serum glucose, HDL-c and low-density lipoprotein cholesterol 
(LDL-c) was less than 10% except for serum glucose (26%), missing values were 
imputed by mean values.  The effects were statistically significant at p-value 0.05. All 
analyses were performed by STATA version 14.0 for Windows.  
Results 
Patient characteristics 
The current study included 15,658 participants without previous history of 
CVD at baseline, approximately 47% of the total sample size of the original ALLHAT 
trial (33,357 participants). As provided in Table 1, on average participants were late 
middle-aged (mean age 65 years), with mildly elevated BP of 146/85 mmHg and a  
moderate10-year FRS of 39% (66% were at high baseline risk). Compared with the 
PT group, TN participants had lower 10-year FRS as they seemed to have more 
optimal CVD risk profiles (e.g. younger, non-Black, no diabetes, lower BMI, lower 
TC, lower serum creatinine), except for a higher proportion of current smokers, 
males, having lower education and higher BP value. After stratification by absolute 
CVD risk, TN participants still had statistically higher BP, lower BMI, a higher 
proportion of males, current smokers and non-DM regardless of risk stratifications. 
When stratified by baseline risk, there were statistically significant differences in age 
in the low and moderate risk group; race in the moderate risk and high-risk group; 
education, LDL-c, serum creatinine, aspirin use and FRS for the high-risk group.  
As reported in Table 2, after randomization, TN participants had statistically 
lower 2- and 4-year systolic BP, a higher rate of participants with BP controlled under 
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140/90 mmHg after two years treatment and under 160/90 mmHg after four years 
treatment although they were likely to receive a smaller number of study drugs and a 
lower rate of medication compliance. When analysed by baseline absolute CVD risk, 
the number of study drugs in the TN group remained statistically smaller than those 
in the PT group. No substantial difference between TN and PT group in low and 
moderate risk groups were recorded regarding average in-trial BP, the rate of BP 
controlled under 140/90 mmHg or under 160/90 mmHg, 2-year medication 
compliance except for 4-year compliance in a low risk group.  Differences between 
TN and PT participants in the high-risk group had similar patterns to those reported 
in the total population.  
Association of ‘treatment naïve’ and mortality (Table 3 and Table 4) 
1,955 total deaths and 675 deaths due to CVD were recorded throughout the 
in-trial period, increasing to 4,761 and 1,422 respectively in 2006 and 7,714 and 
2,126 in 2011.  In unadjusted models, there was a statistically lower risk of short-
term heart failure, 10- and 14-year CVD mortality, 14-year all-cause associated with 
TN group. In model A, after adjustment for major CVD risk factors (age, gender, DM, 
TC, systolic BP, diastolic BP, smoking status) and significantly different baseline 
characteristics (race, BMI, education, aspirin use, randomisation group, glucose, 
creatinine), the association with heart failure was no longer statistically significant. 
However, the TN group was associated with a lower risk of long-term all-cause 
mortality, with HR 0.87 (0.79-0.97) for the 10-year phase and HR 0.90 (0.83-0.97) for 
the 14-year phase, and a lower risk of long-term CVD mortality with HR 0.81 (0.67-
0.98) for the 10-year phase and HR 0.85 (0.73-0.99) for the 14-year phase. In model 
B, when time-dependent variables for BP value and number of in-trial BP lowering 
drug treatment were added in multivariate models, no difference of short- or long-
term mortality outcomes were observed. In subgroup by 10-year Framingham risk 
score, no heterogeneity of relative treatment effects was recorded in either model A 
or B. In sensitivity analysis, multivariate models with further adjustment for HDL-c 
and/or LDL-c did not record any substantial changes to the results seen in model A 
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and B. However, HRs and 95% CI in multivariate models without baseline BPs were 
substantially consistent with those recorded in model B.  
Discussion 
In the current post-hoc observational study of the ALLHAT trial, we found no 
statistically significant difference between participants who were treatment naïve or 
previously treated in either short- or long-term all-cause or cardiovascular mortality. 
The risk ratios were substantially consistent among the low, moderate and high CVD 
risk groups. On average, participants included in this study had moderate 10-year 
CVD risk of 39% and mildly elevated BP 146/89 mmHg. Many differences in baseline 
characteristics between the PT and TN group were observed. As the analysis 
included a large sample size and many statistical tests were performed, some false 
positives were expected. However, some differences in baseline characteristics 
seemed to be clinically meaningful and relevant. For example, PT participants were 
more likely to have lower BP, a lower rate of current smoking, and a higher rate of 
aspirin use. However, they were at higher estimated baseline risk, due to the higher 
proportion of participants having diabetes. Throughout the in-trial phase (median 
time 4.9 years), compared to the PT group, the TN group with smaller numbers of 
medications to reach the treatment target tended to have a larger systolic BP 
reduction (20 mmHg vs 10 mmHg). BPs of TN participants seemed to be more 
controllable than that of PT group because a higher proportion of TN group had 
controlled BP under 140/90 mmHg (68% vs 64%).   
In model A adjusting for baseline characteristics including baseline BPs, 
compared with PT group at a similar BP level, TN group was associated with a 10-
13% lower relative risk of 10- and 14- year all-cause mortality, a 15-19% lower 
relative risk of 10- and 14- year CVD mortality. The results indicate a ‘residual 
cardiovascular risk’  in PT group that is defined as a persisting risk of developing a 
CVD event despite using evidence-based protective therapy such as BP lowering 
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drug treatment 16. Our results are similar to the findings of 10-year CVD mortality 
reported in an individual participant-level meta-analysis by Asayama et al17 and a 
prospective cohort study by Blacher et al18. In a meta-analysis of prospective cohort 
studies in the Japanese general population, Asayama et al found a significantly 
increased risk of 10-year CVD mortality HR 1.50 (1.36-1.66) in previously treated 
participants17. Also, the PRIME cohort study by Blacher et al observed an increased 
risk of 10-year CVD mortality RR 1.62 (1.02–2.58) and a non-statistically increased 
risk of 10-year all-cause mortality RR 1.15 (0.89–1.48) in the previously treated 
group18. Included participants in these two studies were likely to be younger than 
those included in our study. The average BPs of the treated group in the Japanese 
study (146/84 mmHg) remained higher than that of the untreated group (132/79 
mmHg) and 10% of the included participants had a history of CVD events.   
In model B with further adjustment for the varied effects of BP  values and the 
number of study drugs over time (median time 4.9 years), the association between 
‘treatment naïve’ and lower risk of long-term all-cause and CVD mortality in our study 
was attenuated and became non-statistically significant. This was not done in most 
of the above or previous cohort studies 17-19 that conducted a single baseline survey 
and thus information of BP lowering drug treatment and BP values during follow-up 
time were not recorded.  We speculated that the in-trial treatment is an indicator of 
the BP difference when the PT group seemed to have more aggressive drug 
treatment to reach the treatment target. Also, we were concerned that there may be 
unmeasured confounding by indication: that is doctors or physicians preferentially 
treat individuals with higher CVD risk profiles (e.g. subclinical vascular damages or 
family history of CVD) or those who failed to follow lifestyle modifications or were 
exposed to uncontrolled high BP for longer. If these factors could be controlled, 
‘residual risk’ may become less apparent. In contrast, a similar analysis of ANBP212 
in the elderly (>65 years) found a significantly lower risk of 4-year all-cause mortality 
with HR 0.63 (0.46–0.86) and 4-year CVD mortality HR 0.47 (0.27–0.81) in TN 
participants both before and after adjusting for average follow-up BP lowering drug 
treatments and average follow-up BP values. Participants in ANBP2 were older 
(mean age 72 years) and had higher baseline BP (mean BP 168/91 mmHg) than that 
of ALLHAT participants, thus they were more likely to show ‘residual risk’ of BP 
lowering drug treatment.  
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In the subgroup analysis by absolute CVD risk, the analysis recorded no 
statistically significant heterogeneity of the association between ‘treatment naïve’ 
and relative risk of short- or long-term mortality.  In other words, there was no 
difference in relative risk of short- or long-term mortality outcomes between PT and 
TN regardless of baseline estimated 10-year CVD risk stratification. Due to 
significant differences in baseline characteristics between the PT and TN groups, we 
did not estimate the absolute risk reduction. In a meta-analysis of randomised 
controlled trials by Thomopoulos et al20,  in absolute terms, ‘residual risk’ in 5 years 
estimated by incidence rate of all-cause and CVD mortality in the active treatment 
group were higher for higher estimated CVD risk subgroup. However, baseline CVD 
risk estimation in the Thomopoulos et al analysis was based on the actual incidence 
of death rates due to CVD observed in the control groups of the trials. Of note, the 
control groups could be placebo, no treatment or less intensive treatment and 
previous BP lowering drug treatment may have continued in the trial. Thus the 
observed CVD risk in these trials may not be applicable to the estimated risk for 
patients considering treatment. In the HOPE-321 trial in intermediate-risk participants 
with mean BP of 138/82 mmHg, no substantial benefit of active treatment was 
recorded. However, an increased risk of symptomatic hypotension, dizziness and 
light-headedness were observed after a median follow-up time of 5.6 years. 
Similarly, PREVEND-IT8, 9 and Oslo10, 11  trials that had relatively low risk population 
did not record substantial benefits on major CVD event in either 5-year or 10-year 
periods. However, statistically significant effects may not have been achieved 
because these studies were likely to have lacked statistical power (a small number of 
events were seen in this low CVD risk setting). 
Limitations 
ALLHAT was one of the largest hypertension randomised controlled trials ever 
conducted.  After excluding those with a baseline history of CVD, 15658 participants 
were included in the present study. Details of BP lowering drug treatment and BP 
values were closely monitored throughout the in-trial period (median time 4.9 years) 
and the varying effects of these characteristics over time were adjusted in Cox 
regression models. ALLHAT had a very small number of missing values for baseline 
characteristics (<15%) except for serum glucose (26%). Still, there are some 
limitations in our analysis.  
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Our study was biased by ‘confounding by indication’ as mentioned above. 
Also, we were uncertain of the use  of concomitant treatment such as lipid lowering 
drug treatment or aspirin. The study was limited to long-term mortality events; long-
term non-fatal CVD events  such as CHD or stroke were not recorded, and these are 
also a concern for physicians when not treating BP at a traditional systolic BP 
threshold of 140 mmHg. Lack of information on the period of untreated status in TN 
group is one of the major limitations. We considered that these untreated participants 
may have not been diagnosed with hypertension or they did not adhere to the 
treatment. Also, they could be underlying  lifestyle modifications although TN 
participants were likely to have clinically higher rate of smoking compared to PT 
participants (40% vs 28%).  There were some clinical differences in baseline 
characteristics between TN and PT group as mentioned. While statistical 
adjustments were done, such adjustments can not fully control for clinical differences 
and replace randomized observations. This is a post-hoc observational study, and 
statistical power was reduced. However, the length of the post-trial follow-up 
increased the number of events and thus partly improved the statistical power.  As 
with all observational studies, the results may be biased by unmeasured residual 
confounding that increased the imbalance of baseline CVD risk between the PT and 
TN group. The results should be interpreted with caution. 
Conclusions 
 When treatment intensification was taken into consideration in the primary 
prevention population in this study, no adverse legacy effect as a result of baseline 
BP ‘treatment naivety’ was evident in 14 years of follow-up. The non-significant 
associations were consistent across the CVD risk subgroups.  
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Figure 1 Flow diagram of included participants 
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Table 1 Baseline characteristics in total cohort and subgroup by 10-year 
Framingham risk score 
Characteristics TN PT 
 Total  Low Mode
rate 
High Total  Low Mode
rate 
High 
Number of 
observations, n (%) 
 
1657 
(10.6) 
 
299 
(13.6) 
 
386 
(12.0) 
 
972 
(9.5) 
 
14001 
(89.4) 
 
1900 
(86.4) 
 
2819 
(88.0) 
 
9282 
(90.5) 
Age  
(mean + SD, years) 
64.9+ 
7.4 
60.6+ 
5.1 
62.7+ 
6.6 
67.1+ 
7.6 
65.7+ 
7.4 
61.5+ 
5.8 
63.7+ 
6.8 
67.2+ 
7.4 
Black, % 37.4 53.5 38.1 32.2 41.1 50.7 46.9 37.4 
Male, % 56.1 18.4 39.6 74.2 48.1 10.0 28.4 63.4 
Current Smoker, % 40.0 27.1 39.6 44.2 27.6 20.7 23.5 30.2 
Education  
(mean + SD, years)* 
 
10.6+ 
4.3 
 
10.9+ 
4.0 
 
10.8+ 
4.3 
 
10.5+
4.4 
 
10.9+ 
4.0 
 
11.0+ 
3.9 
 
10.8+ 
3.9 
 
10.8+4.
1 
BMI (mean + SD, 
kg/m2)* 
29.1+ 
6.2 
30.0+ 
7.4 
29.6+
6.8 
28.6+
5.5 
30.4+
6.5 
31.1+ 
7.3 
30.9+
7.5 
30.2+6.
0 
Diabetes* (%) 44.3 16.2 34.4 56.1 56.7 23.0 44.8 66.7 
SBPs (mean + SD, 
mmHg): 
        
   1st visit 158+ 
12 
155+ 
13 
159+ 
12 
159+ 
12 
143+ 
13 
138+ 
14 
141+ 
13 
145+ 13 
   2nd visit 156+ 
12 
150+ 
12 
156+ 
12 
158+ 
12 
145+ 
15 
135+ 
14 
141+ 
14 
149+ 15 
DBPs (mean + SD, 
mmHg): 
        
1st visit 91+ 9 92+ 9 92+9 90+ 
10 
83+ 
10 
83+ 9 83+ 9 83+ 10 
2nd visit 90+ 9 90+ 9 90+ 
10 
90+ 9 85+ 
10 
82+ 
10 
84+10 85+ 10 
Laboratory (mean + 
SD, mmol/L): 
        
    Fasting Serum 
Glucose*  
7.1±3.
5 
5.8+ 
2.5 
6.7+ 
3.5 
7.7+ 
3.6 
7.5+ 
3.5 
6.0+ 
2.6 
7.0+ 
3.3 
7.9+ 3.6 
    TC  5.6+ 
1.2 
5.3+ 
1.0 
5.4+ 
1.1 
5.7+ 
1.2 
5.6+ 
1.1 
5.3+ 
1.0 
5.5+ 
1.0 
5.7+ 1.2 
    HDL Cholesterol* 1.2+ 
0.4 
1.5+ 
0.4 
1.3+ 
0.4 
1.1+ 
0.3 
1.2+ 
0.4 
1.5+ 
0.5 
1.3+ 
0.4 
1.1+ 0.3 
    LDL Cholesterol* 3.5+ 
1.0 
3.2+ 
0.9 
3.4+ 
1.0 
3.7+ 
1.0 
3.5+1.
0 
3.1+ 
0.9 
3.4+ 
1.0 
3.6+ 1.0 
   Serum Creatinine* 
(mean + SD, µmol/L) 
86.7+ 
26.5 
80.5 + 
35.4 
84.0 
+ 
35.4 
89.3 + 
26.5 
88.4+ 
26.5 
78.7 + 
17.7 
84.0 + 
26.5 
92.0 + 
26.5 
Aspirin use, % 19.4 16.4 21.8 19.4 23.6 18.9 19.7 25.8 
Estrogen use in 
women, %  
14.7 21.7 14.6 8.0 17.4 26.2 19.8 11.7 
Randomization 
Treatment Group: 
        
    Chlorthalidone 46.0 47.8 47.7 44.9 45.4 45.9 45.3 45.3 
    Amlodipine 27.7 26.1 28.5 27.9 27.5 26.7 28.2 27.5 
    Lisinopril 26.3 26.1 23.8 27.3 27.1 27.4 26.6 27.2 
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Characteristics TN PT 
 Total  Low Mode
rate 
High Total  Low Mode
rate 
High 
Lipid-Lowering 
Randomization 
Group, %: 
        
    Pravastatin 14.4 13.7 11.9 15.5 13.9 11.5 13.2 14.7 
    Usual Care 13.5 14.4 11.7 13.4 14.0 13.4 14.7 14.1 
10-year FRS, mean 
(SD) 
 
36.1+
16.6 
 
14.9+3
.4 
 
25.2+
2.8 
 
46.9+
12.8 
 
40.37
+18.7 
 
15.0+
3.5 
 
25.1+
2.8 
 
50.2+14
.9 
Abbreviations: TN: ‘Treatment Naïve’ group, PT: ‘Previous Treatment’ group. BMI=Body Mass Index, 
DBP=Diastolic Blood Pressure, TC: Total Cholesterol, HDL=high density lipoprotein, LDL= low density 
lipoprotein, SBP=Systolic Blood Pressure, SD=Standard Deviation. FRS: Framingham Risk Score. 
Bold: p<0.05 for the comparison of treatment naïve vs previous treatment. 
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Table 2 In-trial characteristics in total cohort and subgroup by 10-year 
Framingham risk score 
Characteristics TN PT 
 Total  Low Mode
rate 
High Total  Low Moder
ate 
High 
2-year BPs,  
(mean + SD, mmHg)*: 
        
    Systolic BP 136+15 133+15 
136+1
5 
137+1
5 
138+ 
16 
135+1
6 
137+1
6 138+16 
    Diastolic BP 79+9 79+9 80+10 78+9 79+10 80+9 80+10 79+10 
Controlled at <160/90, 
% 
83.5 81.8 81.5 84.8 81.2 82.0  80.4 81.3 
Controlled at <140/90, 
% 
60.2 64.5 55.2 60.9 56.4 62.8 57.8 54.7 
2-year Medication 
Compliance†, % 71.3 72.5 70.2 71.4 72.3 72.8 71.3 72.5 
Number of AHT Meds, 
% 
        
    0 9.8 10.5 9.1 9.9 3.5 3.6 3.3 3.5 
    1 66.2 70.4 67.3 64.4 53.6 61.9 57.8 50.6 
    2 18.3 14.2 18.8 19.4 29.4 25.6 27.8  30.6 
    3+ 5.7 4.9 4.9 6.2 13.5 8.9 11.1 15.2 
4-year BPs, (mean + 
SD, mmHg)*: 
        
    SBP 134 + 15 
133 + 
16 
134 + 
16 
134 + 
145 
135 
+16 
133 + 
15 
134 + 
16 136+ 16 
    DBP 76 + 9 78 + 9 77 + 9 76 + 10 
77 + 
10 78 + 9 78 + 9 77 + 10 
Controlled at <160/90, 
% 
88.9 88.8 89.3 88.9 85.9 86.7 84.6 86.1 
Controlled at <140/90, 
%  
68.0 67.5 67.3 68.5 64.4 69.9 65.2 63.0 
48-year Medication 
Compliance†, % 63.5 59.1 64.7 64.4 66.6 65.1 67.1 66.8 
Number of AHT Meds, 
% 
        
    0 12.2 13.8 12.1 11.7 4.5  6.0 4.5 4.1 
    1 53.9 59.2 53.5 52.3 42.6 50.2 46.9 39.6 
    2 23.9 22.0 21.6 25.4 31.2 29.2 29.7 32.1 
    3+ 10.0 5.0 12.8 10.5 21.7 14.5 18.9 24.1 
Abbreviations: TN: ‘Treatment Naïve’ group, PT: ‘Previous Treatment’ group . AHT=Antihypertensive, 
SBP=Systolic Blood Pressure, DBP: Diastolic Blood Pressure, Hg=Mercury, SD=Standard Deviation. 
†Compliance >80% adherence. Bold: p<0.05 for the comparison of treatment naïve vs previous 
treatment. 
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Table 3 Comparison of CVD events and mortality in ‘treatment naïve’ versus 
‘previous treated’ group in overall population 
 Event n (%) Univariate Multivariate 
Outcome 
Total 
(n=15658) 
TN 
(n=1657) 
PT 
(n=14001) 
 
HR (95% CI) 
 
HR (95% CI)A 
 
HR (95% CI)B 
In-Trial (1994-2002, median time 4.9 years):   
MI 690 (4.4) 64 (3.9) 626 (4.5) 0.89 (0.69-1.16) 0.92 (0.70-1.19) 0.95 (0.73-1.23) 
Stroke 605 (3.9) 63 (3.8) 542 (3.9) 1.03 (0.80-1.34) 0.96 (0.73-1.26) 1.02 (0.78-1.33) 
HF 735 (4.7) 58 (3.5) 677 (4.8) 0.76 (0.58-0.99) 0.83 (0.63-1.09) 0.94 (0.72-1.24) 
New Diabetes 442 (2.8) 57 (3.4) 385 (2.7) 1.16 (0.87-1.53) 1.10 (0.82-1.48) 1.12 (0.84-1.50) 
All-cause mortality 1,955 (12.5) 188 (11.3) 1,767 (12.6) 0.94 (0.81-1.10) 0.91 (0.78-1.06) 0.93 (0.80-1.09) 
CVD mortality 675 (4.3) 61 (3.7) 614 (4.4) 0.84 (0.64-1.09) 0.84 (0.64-1.10) 0.94 (0.72-1.23) 
Post-Trial (1994-2006, median time 9.6 years):    
All-cause mortality 4,761 (30.4) 456 (27.5) 4,305 (30.7) 0.91 (0.82-1.00) 0.87 (0.79-0.97) 0.92 (0.84-1.02) 
CVD mortality 1,422 (9.1) 123 (7.4) 1,299 (9.3) 0.81 (0.67-0.98) 0.81 (0.67-0.98) 0.88 (0.73-1.06) 
Post-Trial (1994-2011, median time 14.1): 
All-cause mortality 7,714 (49.3) 762 (46.0) 6,952 (49.7) 0.92 (0.85-0.99) 0.90 (0.83-0.97) 0.95 (0.88-1.03) 
  CVD mortality 2,126 (13.6) 194 (11.7) 1,932 (13.8) 0.84 (0.73-0.97) 0.85 (0.73-0.99) 0.93 (0.80-1.08) 
Abbreviations: TN: ‘Treatment Naïve’ group, PT: ‘Previous Treatment’ group. MI: Myocardial Infarction. HF: Heart 
Failure. CVD: Cardiovascular Disease. HR = (Cox proportional) hazard ratio. 
Model A: Adjusted for baseline characteristics: age, race, gender, diabetes, education, body mass index, current 
smoking, aspirin use, randomization group, systolic blood pressure, diastolic blood pressure, total cholesterol, gluco  
creatinine 
Model B: Adjusted for baseline characteristics: age, race, gender, diabetes, education, body mass index, current 
smoking, aspirin use, total cholesterol, glucose, creatinine plus time-dependent systolic blood pressure and diastolic 
blood pressure and number of antihypertensive medications. Bold: p<0.05 
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Figure 2.  Comparison of CVD events and mortality in ‘treatment naïve’ versus 
‘previous treated’ in subgroups stratified by 10-year Framingham risk. 
Abbreviations: TN: treatment naïve, PT: previous treatment, CVD: Cardiovascular Disease. 
HR = (Cox proportional) hazard ratio. 
Model A: Adjusted for baseline characteristics: age, race, gender, diabetes, education, body 
mass index, current smoking, aspirin use, randomization group, systolic blood pressure, 
diastolic blood pressure, total cholesterol, glucose, creatinine 
Model B: Adjusted for baseline characteristics: age, race, gender, diabetes, education, body 
mass index, current smoking, aspirin use, total cholesterol, glucose, creatinine plus time-
dependent systolic blood pressure and diastolic blood pressure and number of 
antihypertensive medications. Bold: p<0.05 
  
Favour TN Favour PT 
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